Latest Information Update: 14 Mar 2016
At a glance
- Originator Valeant Pharmaceuticals International
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Actinic keratosis
Most Recent Events
- 13 Jan 2016 Clinical trials in Actinic keratosis in USA (unspecified route) before January 2016